AstraZeneca Pharma, Abbott Healthcare Terminate Distribution Agreements for Diabetes Drug in India

0
440

Image Credit: Shutterstock / Representative

Image Credit: Shutterstock / Representative

On December 7, 2018, AstraZeneca Pharma India and Abbott Healthcare entered into a distribution agreement for the distribution of dapagliflozin.

  • PTI New Delhi
  • Last update:May 28, 2021, 1:43 pm IS
  • FOLLOW US ON:

The pharmaceutical company AstraZeneca Pharma India announced on Friday that it had terminated its distribution agreements with Abbott Healthcare for the type 2 diabetes drug dapagliflozin in India. “AstraZeneca India and Abbott mutually terminated the distribution agreement on May 27, 2021,” said AstraZeneca India in a regulatory filing.

AstraZeneca India will continue to independently market dapagliflozin, the combinations of dapagliflozin and metformin, and dapagliflozin and saxagliptin in India under the brand names Forxiga, Xigduo and Qtern. On December 7, 2018, AstraZeneca Pharma India and Abbott Healthcare entered into a distribution agreement for the distribution of dapagliflozin.

Under this agreement, Abbott has promoted and sold dapagliflozin under the brand name Gledepa and the combination of dapagliflozin with metformin under the brand name Gledepa Met.

.

Read the latest news, breaking news and coronavirus news here